KSS said it rejected the two go-private offers it received from Sycamore Partners and Acacia Research Corp., because they did not adequately value its future growth and cash flow generation potential of the company. In addition, it is adopting a poison pill strategy to prevent a hostile takeover while it evaluates any other offers that come in. The plan grants existing shareholders the right to acquire KSS shares at a 50% discount if any person or entity accumulates more than 10% of the company’s common stock. KSS said that the finance committee of its board of directors will review any ... Log in to view full article.